Applications of gene therapy for familial amyloidotic polyneuropathy

Expert Opinion on Biological Therapy

Volumn 4, Issue 10, 2004, Pages 1621-1627

  Nakamura, Masaaki ^a   Ando, Yukio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Antisense; Chimaeraplasty; Familial amyloidotic polyneuropathy; Gene repair; Gene therapy; Ribozyme; Single stranded oligonucleotides

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; GELSOLIN; METHIONINE; OLIGONUCLEOTIDE; PREALBUMIN; RIBOZYME; SINGLE STRANDED DNA;

AMYLOIDOSIS; CHIMERA; DNA REPAIR; DRUG DELIVERY SYSTEM; FAMILIAL AMYLOID POLYNEUROPATHY; GENE; GENE DELIVERY SYSTEM; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; LIVER TRANSPLANTATION; PLASMA HALF LIFE; PROTEIN EXPRESSION; REVIEW; TTR GENE;

AMYLOID NEUROPATHIES, FAMILIAL; CELLS, CULTURED; DNA REPAIR; DNA, RECOMBINANT; DNA, SINGLE-STRANDED; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; POINT MUTATION; PREALBUMIN; RECOMBINATION, GENETIC; RNA, ANTISENSE; RNA, CATALYTIC; RNA, MESSENGER;

EID: 5644259650     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.10.1621     Document Type: Review

References (68)

1. ANDRADE C: A peculiar form of peripheral neuropathy: familial generalized amyloidosis with special involvement of the peripheral nerves. Brain (1952) 75(3):408-427. First report of patients with FAP.
2. ARAKI S: Type I familial amyloidotic polyneuropathy (Japanese type). Brain. Dev. (1984) 6(2):128-133.
3. ANDERSSON R: Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med. Scand. (1976) 590:1-64.
4. BENSON MD: Familial amyloidotic polyneuropathy. Trends. Neurosci. (1989) 12(3):88-92.
5. BENSON MD, UEMICHI T: Transthyretin amyloidosis. Amyloid (1996) 3(1):44-56.
6. CONNORS LH, LIM A, PROKAEVA T, ROSKENS VA, COSTELLO CE: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid (2003) 10(3):160-184.
7. TAWARA S, NAKAZATO M, KANGAWA K, MATSUO H, ARAKI S: Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem. Biophys. Res. Commun. (1983) 116(3):880-888.
8. AZUMA T, SUZUKI T, MIZUNO R et al.: Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy. Acta Neurol. Scand. (1988) 77(5):409-413.
9. ADACHI N: Current and proposed treatment of familial amyloidotic polyneuropathy. Clin. Neuropharmacol. (1989) 12(6):506-513.
10. SALES-LUIS ML, GALVAO M, CARVALHO M, SOUSA G, ALVES MM, SERRAO R: Treatment of familial amyloidotic polyneuropathy (Portuguese type) by plasma exchange. Muscle Nerve (1991) 14(4):377-378.
11. REGNAULT V, COSTA PM, TEIXEIRA A et al.: Specific removal of transthyretin from plasma of patients with familial amyloidotic polyneuropathy: optimization of an immunoadsorption procedure. Int. J. Artif. Organs. (1992) 15(4):249-255.
12. CARVALHO M, ALVES M, LUIS ML: Octreotide-a new treatment for diarrhoea in familial amyloidotic polyneuropathy. Neurol. Neurosurg. Psychiatry (1992) 55(9):860-861.
13. ANDO Y, GOTOH T, KAWAGUCHI Y, TANAKA Y, SAKASHITA N, ANDO M: Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy. Pharmacotherapy (1995) 15(3):345-349.
14. HOLMGREN G, ERICZON BG, GROTH CG et al.: Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet (1993) 341(8853):1113-1116. First report on liver transplantation in FAP.
15. ERICZON BG, HOLMGREN G, LUNDGREN E, SUHR OB: New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umea, Sweden, June 1999. Amyloid (2000) 7(2):145-147.
16. SKINNER M, LEWIS WD, JONES LA et al.: Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann. Intern. Med. (1994) 120(2):133-134.
17. TAKEI Y, IKEDA S, HASHIKURA Y, IKEGAMI T, KAWASAKI S: Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients. Ann. Intern. Med. (1999) 131(8):592-595.
18. ANDO Y, TANAKA Y, ANDO E et al.: Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet (1995) 345(8943):195-196
19. SUHR O, DANIELSSON A, RYDH A, NYHLIN N, HIETALA SO, STEEN L: Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig. Dis. Sci. (1996) 41(10):1909-1914.
20. LENDOIRE J, TRIGO P, AZIZ H et al.: CUETO G, Liver transplantation in transthyretin familial amyloid polyneuropathy: first report from Argentina. Amyloid (1999) 6(4):297-300.
21. ANDO Y, TERAZAKI H, HARAOKA K et al.: Presence of autoantibody against ATTRVal30Met after sequential liver transplantation. Transplantation (2002) 73(5):674-675.
22. ANDO E, ANDO Y, HARAOKA K: Ocular amyloid involvement after liver transplantation for polyneuropathy. Ann. Intern. Med. (2001) 135(10):931-932.
23. SOMIARI S, GLASSPOOL-MALONE J, DRABICK JJ et al.: Theory and in vivo application of electroporative gene delivery. Mol. Ther. (2000) 2(3):178-187.
24. WARD M, WU J, CHIU JF: Experimental study of the effects of Optison concentration on sonoporation in vitro. Ultrasound Med. Biol. (2000) 26(7):1169-1175.
25. MILLER DL, PISLARU SV, GREENLEAF JE: Sonoporation: mechanical DNA delivery by ultrasonic captation. Somat. Cell Mol. Genet. (2002) 27(1-6):115-134.
26. KAY MA, GLORIOSO JC, NALDINI L: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. (2001) 7(1):33-40.
27. NISHIKAWA M, HUANG L: Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. (2001) 12(8):861-870.
28. YANG Y, LI Q, ERTL HC, WILSON JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. (1995) 69(4):2004-2115.
29. YANG Y, WILSON JM: Clearance of adenovirus-infected hepatocytes by class-I restricted CD4+ CTLs in vivo. J. Immunol. (1995) 155(5):2564-2570.
30. KAY MA, HOLTERMAN AX, MEUSE L et al.: Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet. (1995) 11(2):191-197.
31. VANDENDRIESSCHE T, COLLEN D, CHUAH MK: Biosafety of onco-retroviral vectors. Curr. Gene. Ther. (2003) 3(6):501-515.
32. FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfecrion procedure. Proc. Natl. Acad. Sci. USA (1987) 84(21):7413-7417.
33. THOMAS M, KLIBANOV AM: Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. (2003) 62:27-34.
34. FUJIOKA K, TAKADA Y, SATO S, MIYATA T: Novel delivery system for proteins using collagen as a carrier material: the minipellet. J. Control. Release (1995) 33(2):307-315.
35. OCHIYA T, TAKAHAMA Y, NAGAHARA S et al.: New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the minipellet. Nat. Med. (1999) 5(6):707-710. This article demonstrated that atelocollagen was a novel delivery vehicle for DNA in vivo.
36. LEE CH, SINGLA A, LEE Y: Biomedical applications of collagen. Int. J. Pharm. (2001)221(1-2):1-22.
37. YOON K, COLE-STRAUSS A, KMIEC EB: Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA_DNA oligonucleotide. Proc. Natl. Acad. Sci. USA (1996) 93(5):2071-2076. First report on gene conversion by chimaeraplasts in vitro.
38. COLE-STRAUSS A, YOON K, XIANG Y, BYRNE BC et al.: Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science (1996) 273(5280):1386-1389.
39. SHESELY EG, KIM HS, SHEHEE WR, PAPAYANNOPOULOU T, SMITHIES O, POPOVICH BW: Correction of a human beta S-globin gene by gene targeting. Proc. Natl. Acad. Sci. USA (1991) 88(10):4294-4298.
40. SNOUWAERT JN, BRIGMAN KK, LATOUR AM et al.: An animal model for cystic fibrosis made by gene targeting. Science (1992) 257(5073):1083-1088.
41. SMITHIES O, MAEDA N: Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. Proc. Natl. Acad. Sci. USA (1995) 92(12):5266-5272.
42. MOERSCHELL RP, TSUNASAWA S, SHERMAN F: Transformation of yeast with synthetic oligonucleotides. Proc. Natl. Acad. Sci. USA (1988) 85(2):524-528.
43. YAMAMOTO T, MOERSCHELL RP, WAKEM LP, KOMAR-PANICUCCI S, SHERMAN F: Strand-specificity in the transformation of yeast with synthetic oligonucleotides. Genetics (1992) 131(4):811-819.
44. YAMAMOTO T, MOERSCHELL RP, WAKEM LP, FERGUSON D, SHERMAN F: Parameters affecting the frequencies of transformation and co-transformation with synthetic oligonucleotides in yeast. Yeast (1992) 8(11):935-948.
45. KOTANI H, GERMANN MW, ANDRUS A, VINAYAK R, MULLAH B, KMIEC EB: RNA facilitates Rec-A-mediated DNA pairing and strand transfer between molecular bearing limited regions of homology. Mol. Gen. Genet. (1996) 250(5):626-634. This article shows that RNA can reduce the length of homology required for strand exchange.
46. COLE-STRAUSS A, GAMPER H, HOLLOMAN WK, MUNOZ M, CHENG N, KMIEC EB: Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell-free extract. Nucleic Acid. Res. (1999) 27(5):1323-1330.
47. CAMPER HB JR, COLE-STRAUSS A, METZ R, PAREKH H, KUMAR R, KMIEC EB: A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry (2000) 39(19):5808-5816.
48. CAMPER HB, PAREKH H, RICE MC, BRUNER M, YOUKEY H, KMIEC EB: The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res. (2000) 28(21):4332-4339. This article reported that gene repair by SSOs was as effective as chimaeraplasts.
49. LU H, FISHER RP, BAILEY P, LEVINE AJ: The CDK7-cycH-p36 complex of transcription Factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol. Cell. Biol. (1997) 17(10):5923-5934.
50. RICE MC, CZYMMEK K, KMIEC EB: The potential of nucleic acid repair in functional genomics. Nat. Biotechnol. (2001) 19(4):321-326.
51. LIU L, RICE MC, KMIEC EB: In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides. Nucleic Acids Res. (2001) 29(20):4238-4250.
52. LIU L, CHENG S, VAN BRABANT AJ, KMIEC EB: Rad51p and Rad54p, but not Rad52p, elevate gene repair in Saccharomyces cerevisiae directed by modified single-stranded oligonucleotide vectors. Nucleic Acids Res. (2002) 30(13):2742-2750. This article was the first to show that Rad51 stimulated gene repair in yeast.
53. LIU L, RICE MC, DRURY M, CHENG S, CAMPER H, KMIEC EB: Strand bias in targeted gene repair is influenced by transcriptional activity. Mol. Cell. Biol. (2002) 22(11):3852-3863.
54. METZ R, DICOLA M, KURIHARA T et al.: Mode of action of RNA/DNA oligonucleotides progress in the development of gene repair as a therapy for α(1)-antittypsin deficiency. Chest (2002) 121(3 Suppl.):91-97.
55. GAMPER HB, NULF CJ, COREY DR, KMIEC EB: The synaptic complex of RecA protein participates in hybridization and inverse strand exchange reactions. Biochemistry (2003) 42(9):2643-2655.
56. BRACHMAN EE, KMIEC EB: Targeted gene repair of cyc 1 mutations in Saccharomyces cerevisiae directed by modified single-stranded DNA oligonucleotides. Genetics (2003) 163(2):527-538.
57. ANDERSEN MS, SORENSEN CB, BOLUND L, JENSEN TG: Mechanisms underlying targeted gene correction using chimeric RNA/DNA and single-stranded DNA oligonucleotides. J. Mol. Med. (2002) 80(12):770-781. This article is a valuable review of oligonucleotide targeting, including the mechanisms involved.
58. PROPSTING MJ, BLASCHKE M, HAAS RE et al.: Inosine(15.1)-Hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem. Biophys. Res. Commun. (1999) 260(2):313-317.
59. TANAKA K, YAMADA T, OHYAGI Y, ASAHARA H, HORIUCHI I, KIRA J: Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J. Neurol. Sci. (2001) 183(1):79-84. This article shows the possibility of gene therapy by ribozymes in FAP.
60. ANDO Y, YAMASHITA T, NAKAMURA M et al.: Down regulation of a harmful variant protein by replacement of its normal protein. Biochim. Biophys. Acta (1997) 1362(1):39-46.
61. JOUQUAN J, PENNEC Y, MOTTIER D et al.: Retinol carrier protein, prealbumin and transferrin. Influence of age and sex on the serum concentration of proteins with a short half-life. Presse Med. (1983) 12(30):1877.
62. DICKSON PW, HOWLETT GJ, SCHREIBER G: Metabolism of prealbumin in rats and changes induced by acute inflammation. Eur. J. Biochem. (1982) 129(2):289-293.
63. ANDO Y, TANAKA Y, NAKAZATO M et al.: Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem. Biophys. Res. Commun. (1995) 211(2):354-358.
64. KREN BT, BANDYOPADHYAY P, STEER CJ: In vivo site-directed mutagenesis of the Factor IX gene by chimeric RNA/DNA oligonucleotide. Nat. Med. (1998) 4(3):285-290. This article shows in vivo effect of chimaeraplasts in animals.
65. KREN BT, PARASHAR B, BANDYOPADHYAY P, CHOWDHURY NR, CHOWDHURY JR, STEER CJ: Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide. Proc. Natl. Acad. Sci. USA (1999) 96(18):10349-10354.
66. NAKAMURA M, ANDO Y, NAGAHARA S et al.: Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther. (2004) 11(10):838-846. This article was the first to present the possibility of gene repair by SSOs in FAP.
67. TAGALAKIS AD, GRAHAM IR, RIDDELL DR, DICKSON JG, OWEN JS: Gene conversion of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty. J. Biol. Chem. (2001) 276(16):13226-13230.
68. LIU L, PAREKH-OLMEDO H, KMIEC EB: The development and regulation of gene repair. Nat. Rev. Genet. (2003) 4(9):679-689.